Table 1.

Demographic and clinical characteristics of patients with SLE.

SLE
N = 102
Adherent
n = 54
Overdue
n = 48
P
Age, yrs, mean (SD)41 (13)42 (12)41 (14)0.73*
Race, n/N (%)
      White22/49 (44.9)22/45 (48.9)0.69**
      Afrodescendant27/49 (55.1)23/45 (51.1)
Disease duration, yrs, mean (SD)13 (8)13 (7)14 (9)0.68*
Clinical manifestations, n (%)
      Nephritis55 (56.1)31 (58.5)24 (53.3)0.45**
      Neuropsychiatric6 (6.1)3 (5.7)3 (6.7)0.88**
      Hematologic41 (41.8)22 (41.5)19 (42.2)0.97**
      Arthritis78 (79.6)44 (83)34 (75.6)0.55**
      Serositis40 (48.8)22 (41.5)18 (40)0.73**
      Mucocutaneous72 (73.5)41 (77.4)31 (68.9)0.20**
SDI score, median (IQR)1 (0-5)1 (0-5)0 (0-2)0.03***
      SDI ≥ 1, n/N (%)50/99 (50.5)32/53 (60.3)18/46 (39.1)0.03**
Treatment, n (%)
      Hydroxychloroquine82 (80)43 (79.6)39 (81)0.85**
      Prednisone ≥ 5 mg71 (69.6)36 (66)35 (72.9)0.49**
      Immunosuppressant or biologicsa55 (53.9)31 (57.4)24 (50)0.45**
  • * t test.

  • ** Chi square test.

  • *** Mann-Whitney U test.

  • a Azathioprine, cyclophosphamide, mycophenolate mofetil, rituximab, belimumab. SLE: systemic lupus erythematosus; SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.